Clinical Trial: A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus(R) in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations

U.S., May 20 -- ClinicalTrials.gov registry received information related to the study (NCT07597668) titled 'A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus(R) in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations' on April 13.

Brief Summary: The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in comparison with the drug product Ocrevus(R) (F. Hoffmann-La Roche Ltd., Switzerland) when used in patients with multiple sclerosis (MS)

Study Start Date: April 16, 2025

Study T...